Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VT-A1
- Development stage
- Preclinical
- Lead developer
- VASTHERA
- Modality
- Small Molecules
01
Overview
VT-A1 is a preclinical small molecule drug candidate developed by VASTHERA for the treatment of Alzheimer's disease. It is built on the company's proprietary Redoxizyme™ platform, which focuses on the development of small-molecule peroxiredoxin (Prx) nanozymes. These compounds are designed to mimic the catalytic antioxidant activity of natural peroxiredoxin enzymes, which are essential for neutralizing reactive oxygen species (ROS) and maintaining cellular redox homeostasis. By reducing oxidative stress and potentially mitigating neuroinflammation—key drivers of neurodegeneration—VT-A1 aims to address fundamental pathological processes in Alzheimer's disease.
02
Targets
PRDX2 (Peroxiredoxin-2)
Beyond the preview
Go deeper on VT-A1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VT-A1.